PARP1 and ovarian carcinoma: Niraparib is an oral PARP inhibitor which was investigated in a randomized, double-blind, Phase 3 trial (NOVA) to study the clinical efficacy of maintenance niraparib in platinum-sensitive, recurrent ovarian cancer patients who had received at least two previous lines of platinum-based treatment (registered with ClinicalTrials.gov, #NCT01847274) [36].